Cargando…

De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis

Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidovic, Tamara, Schimpf, Judith, Sprenger-Mähr, Hannelore, Abbassi-Nik, Armin, Soleiman, Afschin, Zitt, Emanuel, Lhotta, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556126/
https://www.ncbi.nlm.nih.gov/pubmed/34254648
http://dx.doi.org/10.1155/2021/8400842
_version_ 1784592120413159424
author Davidovic, Tamara
Schimpf, Judith
Sprenger-Mähr, Hannelore
Abbassi-Nik, Armin
Soleiman, Afschin
Zitt, Emanuel
Lhotta, Karl
author_facet Davidovic, Tamara
Schimpf, Judith
Sprenger-Mähr, Hannelore
Abbassi-Nik, Armin
Soleiman, Afschin
Zitt, Emanuel
Lhotta, Karl
author_sort Davidovic, Tamara
collection PubMed
description Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients.
format Online
Article
Text
id pubmed-8556126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85561262021-10-30 De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis Davidovic, Tamara Schimpf, Judith Sprenger-Mähr, Hannelore Abbassi-Nik, Armin Soleiman, Afschin Zitt, Emanuel Lhotta, Karl Case Rep Nephrol Case Report Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients. Hindawi 2021-10-22 /pmc/articles/PMC8556126/ /pubmed/34254648 http://dx.doi.org/10.1155/2021/8400842 Text en Copyright © 2021 Tamara Davidovic et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Davidovic, Tamara
Schimpf, Judith
Sprenger-Mähr, Hannelore
Abbassi-Nik, Armin
Soleiman, Afschin
Zitt, Emanuel
Lhotta, Karl
De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title_full De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title_fullStr De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title_full_unstemmed De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title_short De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
title_sort de novo and relapsing glomerulonephritis following sars-cov-2 mrna vaccination in microscopic polyangiitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556126/
https://www.ncbi.nlm.nih.gov/pubmed/34254648
http://dx.doi.org/10.1155/2021/8400842
work_keys_str_mv AT davidovictamara denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT schimpfjudith denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT sprengermahrhannelore denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT abbassinikarmin denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT soleimanafschin denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT zittemanuel denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis
AT lhottakarl denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis